Working…
ClinicalTrials.gov

Key Record Dates

ClinicalTrials.gov Identifier: NCT03037385
Brief Title: Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors (ARROW)

First Submitted : January 20, 2017
First Submitted that Met QC Criteria : January 27, 2017
First Posted : January 31, 2017 (Estimate)

Last Update Submitted that Met QC Criteria : October 9, 2021
Last Update Posted : October 12, 2021